argenx SE (ARGX.BR)
75.40EUR
9:48am BST
€0.20 (+0.27%)
€75.20
€75.50
€75.50
€74.80
3,459
49,392
€88.60
€16.75
About
Overall
| Beta: | -- |
| Market Cap(Mil.): | €583.54 |
| Shares Outstanding(Mil.): | 26.89 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ARGX.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 32.76 |
| EPS (TTM): | -1.07 | -- | -- |
| ROI: | -19.69 | 1.78 | 14.61 |
| ROE: | -19.69 | 3.28 | 16.33 |
BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod
* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS
BRIEF-Argenx Q1 Operating Income Down At 6.9 Million Euros
* ARGENX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
BRIEF-Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)
* REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING
BRIEF-Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma
* TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX
BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer
* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer
* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)
BRIEF-Argenx To Present Complete Data From Phase 2 Clinical Trial Of Efgartigimod
* TO PRESENT COMPLETE DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD (ARGX-113) IN MYASTHENIA GRAVIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
BRIEF-Argenx Announces Orphan Drug Designation For Argx-113 For Treatment Of Myasthenia Gravis In Europe
* ANNOUNCES ORPHAN DRUG DESIGNATION FOR ARGX-113 FOR TREATMENT OF MYASTHENIA GRAVIS IN EUROPE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
BRIEF-Argenx Reports Fourth Quarter Business Update And Full Year 2017 Financial Results
* ARGENX REPORTS FOURTH QUARTER BUSINESS UPDATE AND FULL YEAR 2017 FINANCIAL RESULTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
BRIEF-Argenx FY Total Operating Income Rises To 41.3 Million Euros
* FY REVENUE EUR 36.4 MILLION VERSUS EUR 14.7 MILLION YEAR AGO
Estimates